Logo

Lexicon Genetics Lands Merck as Licensee

Aug 23, 2001

NEW YORK, Aug. 15 – Merck has acquired a non-exclusive license to Lexicon Genetics' gene-targeting technologies, bringing to 16 the total number of licensees for the technologies, Lexicon said on Wednesday.

Details of the agreement were not disclosed.

Lexicon Genetics, of The Woodlands, Texas, uses gene-knockout technology to identify genes of medical interest. In addition to licensing this technology, Lexicon uses it to develop its own drug-discovery efforts.

Lexicon also sells subscriptions to its LexVision database of mouse gene-knockout data, which includes physiological data such as measurements of whole blood-cell count, X-rays, MRI and CT scans, and certain neurological tests. 

Last week, Lexicon announced that GlaxoSmithKline agreed to a multi-year, non-exclusive sublicense to Lexicon Genetics' gene targeting technologies. Under the terms of the agreement, GlaxoSmithKline will pay an undisclosed one-time fee. 

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.